drugset / Trial / NCT00192465
Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults
RandomizedParallel-groupOpen-labelPrevention
Summary
To provide safety, tolerability, pharmacokinetic, and immunogenicity data for MEDI-524 administered initially as a single dose to healthy adults in a dose escalation safety study before testing in the targeted pediatric population.
Timeline
- Start
- 2003-11
- Primary completion
- 2004-04
- Completion
- 2004-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Motavizumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Motavizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Motavizumab | Monoclonal antibody | 30 mg/kg | Intravenous |